Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04359407
Other study ID # 2020-00896
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 27, 2020
Est. completion date May 10, 2021

Study information

Verified date July 2021
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity. The purpose of the study is to quantify with the electrical impedance tomography (EIT) the changes in the ventilation and aeration in the dorsal regions of the lung when the patient is placed in prone position.


Description:

Patients with acute respiratory distress syndrome (ARDS) frequently develop atelectasis in dorsal lung regions because of gravity and the compression by the heart and the diaphragm. Since lung perfusion is predominantly distributed in lower lung regions, a reduction of ventilation in these areas results in further ventilation-perfusion mismatch, called shunt. The development of atelectatic lung regions necessitate the use of higher ventilation pressures, which in turn results in excessive transpulmonary pressures and ventilation-induced lung injury in the ventral regions. Therefore it is common to promote the prone position in patients with ARDS in order to improve ventilation-perfusion matching and thus, protect the ventral regions from hyperinflation. In patients with COVID-19-related ARDS, the value of such therapeutic strategy based on placing in prone position has not been completely elucidated. The aims of the study are to determine whether prone positioning improves dorsal regional ventilation when compared to supine position. Moreover, another aim is to assess the changes in intrapulmonary shunt following patient position changes.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date May 10, 2021
Est. primary completion date May 10, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients fulfilling all the following criteria are eligible for the study: - Mechanically ventilated - Fit the Berlin Definition for moderate or severe acute respiratory distress syndrome (arterial oxygen partial pressure over inspiratory fraction of oxygen less than 200 mmHg) - Infection with coronavirus confirmed - Scheduled to undergo prone positioning Exclusion Criteria: - Patients with pacemakers, defibrillators or other electrically active implants - Patients with damaged skin or impaired skin contact of the electrodes due to wound dressings - Patients with chest tubes - History of thoracic surgery or lung resection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Prone positioning
Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone

Locations

Country Name City State
Switzerland University Hospitals of Geneva Geneva

Sponsors (1)

Lead Sponsor Collaborator
Walid HABRE

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tidal electrical Impedance Change in the ratio of tidal electrical impedance variation in the dorsal and total lung areas One hour before turning to prone or supine positioning
Secondary Intrapulmonary shunt Changes in intrapulmonary shunt fraction One hour before turning to prone or supine positioning
Secondary Volumetric capnography Changes in the phase three slope of the volumetric capnogram One hour before turning to prone or supine positioning
See also
  Status Clinical Trial Phase
Recruiting NCT05543616 - A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Phase 2/Phase 3
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Completed NCT04334044 - Treatment of SARS Caused by COVID-19 With Ruxolitinib Phase 1/Phase 2
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Recruiting NCT04466241 - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Phase 2/Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT04402879 - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals N/A
Recruiting NCT04661631 - Surgery and Lung Ultrasound in COVID-19 Infection
Completed NCT04376476 - Host-pathogen Interactions During SARS-CoV-2 Infection N/A
Completed NCT04375098 - Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Phase 2
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04354779 - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting NCT04367207 - African Covid-19 Critical Care Outcomes Study
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Completed NCT04602351 - Communication in ICU During COVID-19
Terminated NCT04707703 - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Phase 3
Active, not recruiting NCT04987528 - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed NCT04667936 - Evaluation of Sedation in COVID-19 ARDS
Completed NCT04423770 - COVID-19 Related Health and Infection Control Practices Among Dentists